Q1 EPS Forecast for Apellis Pharmaceuticals Cut by Analyst

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at Wedbush lowered their Q1 2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a research note issued on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.46) for the quarter, down from their previous forecast of ($0.43). Wedbush currently has a “Neutral” rating and a $29.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.59) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $2.05 EPS and FY2029 earnings at $3.50 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. During the same quarter in the previous year, the firm earned ($0.73) earnings per share. The firm’s revenue was up 45.2% on a year-over-year basis.

APLS has been the topic of a number of other reports. JPMorgan Chase & Co. increased their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Royal Bank of Canada dropped their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a research report on Monday, March 3rd. The Goldman Sachs Group reduced their price objective on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Finally, Scotiabank lifted their price target on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.59.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $18.20 on Friday. Apellis Pharmaceuticals has a 1 year low of $17.49 and a 1 year high of $50.98. The stock has a market cap of $2.28 billion, a PE ratio of -8.97 and a beta of 0.85. The stock has a fifty day moving average price of $23.72 and a 200 day moving average price of $28.00. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Boxer Capital Management LLC purchased a new stake in Apellis Pharmaceuticals during the 4th quarter worth approximately $45,504,000. National Bank of Canada FI raised its holdings in Apellis Pharmaceuticals by 266,361.5% in the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company’s stock valued at $44,214,000 after acquiring an additional 1,385,080 shares in the last quarter. Royal Bank of Canada grew its holdings in Apellis Pharmaceuticals by 969.6% during the 4th quarter. Royal Bank of Canada now owns 1,518,827 shares of the company’s stock worth $48,465,000 after acquiring an additional 1,376,832 shares in the last quarter. Cibc World Markets Corp acquired a new stake in shares of Apellis Pharmaceuticals in the 4th quarter valued at about $41,014,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Apellis Pharmaceuticals during the fourth quarter worth about $40,461,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Transactions at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 3,323 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $101,118.89. Following the completion of the transaction, the general counsel now directly owns 144,994 shares in the company, valued at approximately $4,412,167.42. This represents a 2.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Cedric Francois sold 13,551 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $412,356.93. Following the completion of the transaction, the chief executive officer now owns 418,519 shares in the company, valued at $12,735,533.17. This represents a 3.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,011 shares of company stock valued at $1,059,969 over the last 90 days. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).